Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

Study acronym: MARITIME-PEN
StatusNot Yet Recruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Amgen
169 trials monitored
See 11 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
Trial Details
NCT Number NCT07871409
Lead Sponsor Amgen
Conditions
(from sponsor)		 Obesity, Overweight
Related terms Obesity, Overweight
Enrollment 230 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov